Vincent J. Picozzi

Dr. Vincent J. Picozzi

Oncology
1100 Ninth Avenue, 
Seattle, WA 
Accepting New Patients
Offers Telehealth
1100 Ninth Avenue, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Vincent Picozzi, Jr., MD, specializes in pancreatic cancer, gastrointestinal cancer (pancreaticobiliary), genitourinary cancer, hematologic oncology (lymphomas) and myelodysplasia.

Dr. Picozzi is rated as an Experienced provider by MediFind in the treatment of Glioblastoma. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Pancreaticoduodenectomy, and Pancreatectomy.

His clinical research consists of co-authoring 41 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
MD, Stanford University School Of Medicine, CA, ; MS, Health Administration, Tulane University, New Orleans - 1978,1999
Residency
Internal Medicine, Harvard University, Brigham and Women's Hospital, Boston - 1981
Specialties
Oncology
Licenses
Internal Medicine in WA
Board Certifications
American Board Of Internal Medicine, Subspecialty In Hematology, Subspecialty In Medical Oncology
Fellowships
Hematology, Stanford University, CA, ; Oncology, Stanford University, CA - 1984
Hospital Affiliations
Virginia Mason Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Virginia Mason Medical Center
1100 Ninth Avenue, Seattle, WA 98101

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Precision Promise Platform Trial for Metastatic Pancreatic Cancer
Precision Promise Platform Trial for Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug
Study Drugs: Gemcitabine, Nab-paclitaxel, SM-88, mFOLFIRINOX
Study Phase: Phase 3
A Single Arm Phase Ib/II Multi-Center Study of Nivolumab in Combination With Nanoliposomal-Irinotecan, 5-Fluorouracil, and Leucovorin as Second Line Therapy for Patients With Advanced Biliary Tract Cancer
A Single Arm Phase Ib/II Multi-Center Study of Nivolumab in Combination With Nanoliposomal-Irinotecan, 5-Fluorouracil, and Leucovorin as Second Line Therapy for Patients With Advanced Biliary Tract Cancer
Enrollment Status: Completed
Publish Date: December 18, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer Whose Disease Has Progressed or Recurred
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer Whose Disease Has Progressed or Recurred
Enrollment Status: Terminated
Publish Date: November 06, 2024
Intervention Type: Drug
Study Drugs: SM-88, MPS (methoxsalen, phenytoin, sirolimus), Capecitabine, Gemcitabine, 5-FU
Study Phase: Phase 2/Phase 3
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
Enrollment Status: Completed
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drugs: Pamrevlumab, Gemcitabine, Nab-paclitaxel, FOLFIRINOX
Study Phase: Phase 3
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 31, 2024
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
A Phase IIa, Multicenter, Open-label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study (KEYNOTE-202)
A Phase IIa, Multicenter, Open-label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study (KEYNOTE-202)
Enrollment Status: Completed
Publish Date: August 28, 2024
Intervention Type: Drug
Study Drugs: BL-8040, Pembrolizumab, Chemotherapy of Onivyde
Study Phase: Phase 2
A Randomized, Open Label, Phase 1/2 Trial of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 as Neoadjuvant Chemotherapy in Locally Advanced, Unresectable Pancreatic Cancer
A Randomized, Open Label, Phase 1/2 Trial of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 as Neoadjuvant Chemotherapy in Locally Advanced, Unresectable Pancreatic Cancer
Enrollment Status: Completed
Publish Date: March 02, 2023
Intervention Type: Drug
Study Drugs: FG-3019, Gemcitabine, Nab-paclitaxel
Study Phase: Phase 1/Phase 2
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer
Enrollment Status: Completed
Publish Date: August 12, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Drug
Study Phase: Phase 1
An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination With Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma
An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination With Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma
Enrollment Status: Completed
Publish Date: November 20, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

41 Total Publications

Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study.
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 31, 2025
Similar Doctors
Distinguished in Glioblastoma
Dr. Lynne Taylor
Neurology | Hematology Oncology | Hematology
Distinguished in Glioblastoma
Dr. Lynne Taylor
Neurology | Hematology Oncology | Hematology

The Association Of University Physicians

1959 Ne Pacific St, 
Seattle, WA 
 (2.9 miles away)
206-598-4333
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lynne Taylor is a Neurologist and a Hematologist Oncology provider in Seattle, Washington. Dr. Taylor is rated as a Distinguished provider by MediFind in the treatment of Glioblastoma. Her top areas of expertise are Glioblastoma, Brain Tumor, Astrocytoma, and Glioma.

Distinguished in Glioblastoma
Dr. Vyshak Alva-Venur
Oncology | Hematology Oncology
Distinguished in Glioblastoma
Dr. Vyshak Alva-Venur
Oncology | Hematology Oncology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (1.2 miles away)
206-288-1000
Languages Spoken:
English, Castilian, Finnish, Hindi, Kannada, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Vyshak Alva-Venur is an Oncologist and a Hematologist Oncology provider in Seattle, Washington. Dr. Alva-Venur is rated as a Distinguished provider by MediFind in the treatment of Glioblastoma. His top areas of expertise are Glioblastoma, Embryonal Tumor with Multilayered Rosettes, Gliosarcoma, and Neuroepithelioma. Dr. Alva-Venur is currently accepting new patients.

Distinguished in Glioblastoma
Dr. Mijung Lee
Hematology | Oncology
Distinguished in Glioblastoma
Dr. Mijung Lee
Hematology | Oncology
4525 3rd Avenue Southeast, Suite 200, 
Lacey, WA 
 (46.2 miles away)
360-754-3934
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mijung Lee is a Hematologist and an Oncologist in Lacey, Washington. Dr. Lee is rated as a Distinguished provider by MediFind in the treatment of Glioblastoma. Her top areas of expertise are Angiosarcoma, Paget Disease of the Breast, Inflammatory Breast Cancer, Astrocytoma, and Bone Marrow Aspiration. Dr. Lee is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Picozzi's expertise for a condition
ConditionClose
View All 18 Advanced Conditions
View All 66 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile